Viralytics (ASX:VLA) announced that its Cavatak cancer treatment showed signs of oncolytic activity during a phase II trial, and of synergy with a new class of cancer therapy during lab tests. [ + ]

Melbourne-based biotech company Starpharma has signed an expanded agreement with biopharma company AstraZeneca in the field of cancer medicine. The new agreement will see the application of Starpharma's dendrimer technology to a cancer drug from AstraZeneca's pipeline. [ + ]

CSIRO's chief executive, Dr Megan Clark, has provided an update into new operating arrangements at the organisation. The changes are aimed at making things easier for both staff and those doing business with CSIRO. [ + ]

Hong Kong's 'Soft-landing Programme for Technology and Innovation Collaboration' is open to technology transfer offices (TTOs), research and development centres, research institutes and spin-out companies of overseas universities interested in exploring the Asian market, especially mainland China. [ + ]

Regeneus (ASX:RGS) has selected Hennessy Research to manufacture its canine cancer immunotherapy Kvax for the marketing trials and product launch in the US. [ + ]

Reva sticks to expediting its biodegradable stent Fantom to the clinic. [ + ]

Melbourne's Global Kinetics will present details of the company and its Parkinson's Kinetograph symptom-monitoring device at a global philanthropic forum in New York in May.  

Patrys (ASX:PAB) has published data on a study involving using a plant-based production system to produce IgM antibodies such as the company's anticancer candidate PAT-SM6. [ + ]

The first round of a new pilot funding program opens this week in Queensland, with at least $2 million available for biopharmaceutical product developers wanting to make use of BioPharmaceuticals Australia's (BPA) new mammalian cell contract manufacturing facility, operated by DSM Biologics (DSMB). [ + ]

The IgM antibody PAT-SM6, developed by biotechnology company Patrys, has been produced through a plant-based manufacturing system. [ + ]

The Australian Nuclear Science and Technology Organisation (ANSTO), located in Sydney's Sutherland Shire, is once again holding its Easter school science workshops. [ + ]

Researchers have conducted the largest randomised, double-blind, placebo-controlled study to date on the effect of OnabotulinumtoxinA (OBA, or Botox) on depression. [ + ]

Preparing grant proposals for a single annual deadline is stressful, time-consuming and conflicts with personal responsibilities, a study confirms. [ + ]

Antisense Therapeutics' (ASX:ANP) in-licensed MS drug candidate ATL1102 was found to be well tolerated at two dose levels during a long-term animal trial. [ + ]

Shares in Prana Biotechnology (ASX:PBT) fell 73% after the company revealed that a phase II trial of PBT2 in Alzheimer's disease did not meet its primary and some secondary endpoints. [ + ]